- Research Institute
- About Us
- Anesthesiology
- Cardiology
- Cardiothoracic Surgery
- Donation Information
- Endocrinology & General Medicine
- Gastroenterology
- Genetics/Genomics
- In-Patient Medicine
- Interventional Neuroradiology
- Neurology
- Northwest Community Clinical Oncology Program
- Oncology & Hematology
- Other Research Programs
- Research Institute Staff
- Surgery
Post Heart Attack Study - ACZ
Title: ACZ 8851 A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with persistently elevated hsCRP
Purpose: This trial will compare Canakinumab to Placebo as secondary prevention in post-MI patients.
Who Can Participate?
Diagnosis or Condition: Patients who have had an MI more than 30 days ago
Age: 18 yrs or older
Sex: Males and Females
Visits: Event Driven – 19 visits (quarterly) up to 4 years
Stipend: You will be compensated for your time and travel
Principal Investigator: Vinay Malhotra, MD
Study Coordinator: Jessica Ebert, 253-403-7435 or Wendy Carnahan, 253-403-7249
For more information, contact the Study Coordinator and reference Novartis ACZ trial.